Facilitated By

San Antonio Medical Foundation

News

  • Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination

    ... San Antonio Breast Cancer Symposium on Wednesday. Already registered ... Krystal Biotech Expects CHMP Opinion on Skin Condition Gene Therapy in Early ...

  • Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and ...

    ... San Antonio Breast Cancer Symposium highlighting the activity the ... Sarepta, Biotech's Regulatory Go-Getter, Signs Standout Rare Disease Deal.

  • Celcuity's Breast Cancer Drug Shows Breakthrough 77-Month Survival Data in Clinical Trial

    The data was presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. ... Celcuity is a clinical-stage biotechnology ...

  • Authorities say the mystery disease in Congo might be malaria but more testing is needed

    ... Biomedical Research in Kinshasa, told The Associated Press. ... Officer William Kasberg of the San Antonio Police Department's DWI unit gives a field ...

  • Cancer therapy shows long-term survival benefits for patients with high-risk, BRCA-positive ...

    Biomedical technology · Cardiology · Dentistry · Diabetes · Diseases ... San Antonio Breast Cancer Symposium (SABCS), held December 10–13, 2024 ...